Pin43 - A Cost-Effectiveness Analysis of Revaccinating Older Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (Ppv23) Compared to Vaccinating With a Single Dose of Ppv23 in the United Kingdom (Uk)

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1362
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PIN64 Assessing the Cost-Effectiveness (CE) of Vaccinating the Elderly and At-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) or No Vaccination (NoVac) in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

A Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Healthy Children, Adults, and Elderly

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2018English

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds With the 13-Valent Pneumococcal Conjugate Vaccine in England

PLoS ONE
Multidisciplinary
2016English

The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Rheumatoid Arthritis

Epidemiology and Vaccine Prevention
2015English

Efficacy and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Rheumatoid Arthritis

The Clinician
2015English

Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine

Infection and Immunity
ParasitologyInfectious DiseasesImmunologyMicrobiology
2000English

Public and Private Payer Perspectives on the Net Cost of Implementation of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Compared With 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

MMWR. Morbidity and mortality weekly report
Health Information ManagementMutagenesisEpidemiologyHealthMedicineToxicology
2019English

PIN54 Cost-Effectiveness of 2+1 Dosing of 13-Valent Pneumococcal Conjugate Vaccine Compared With 2+1 Dosing of 10-Valent Conjugate Vaccine in Preventing Pneumococcal Disease in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy